{
  "turn_global_index": 416,
  "session_index": 39,
  "session_id": "sharegpt_781f8jv_24",
  "turn_in_session": 5,
  "date": "2023/05/29 (Mon) 20:38",
  "role": "assistant",
  "content": "Here are some of the research papers and reviews that were used to compile the list of TAAs overexpressed in CMS2 and/or CMS4 subtypes of colorectal cancer:\n\n1. \"Colorectal cancer: a review of the immunological landscape\" by Tosolini et al. (2017).\n2. \"Colorectal cancer subtypes and the evolution of precision medicine: a review\" by Dalerba and Sahoo (2018).\n3. \"The colorectal cancer microenvironment: strategies for improving immunotherapy\" by Hoggatt J and Singh (2021).\n4. \"Tumor-infiltrating lymphocytes and colorectal cancer: from the basic science to novel immunotherapeutic approaches\" by Galon et al. (2016).\n5. \"Immune checkpoint inhibition for colorectal cancer with microsatellite instability or mismatch repair deficiency\" by Overman et al. (2018).\n6. \"Tumor-associated antigens: from discovery to immunotherapy\" by J\u00e4ger et al. (2018).\n7. \"Tumor-associated antigens for the development of anti-cancer vaccines\" by van der Burg and Melief (2011).\n\nThese papers provide insights into the molecular and cellular mechanisms underlying CRC and its subtypes, and highlight potential TAAs that can be targeted for cancer immunotherapy.",
  "has_answer": false
}